Blueprint Medicines (BPMC) Reports Q3 Loss of $1.93/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Blueprint Medicines (BPMC) Reports Q3 Loss of $1.93/Share

Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results

November 5, 2019 7:00 AM EST

CAMBRIDGE, Mass., Nov. 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, is hosting its first R&D Day in New York City today. 

During the event, Blueprint Medicines will outline its vision to become a leading platform-enabled, fully-integrated, global precision therapy company. The R&D Day presentation will highlight opportunities to expand the reach of... More